Do the effects of secondary prevention of cardiovascular events in PAD patients differ from other atherosclerotic disease?

International Journal of Molecular Sciences

Volumn 16, Issue 7, 2015, Pages 14477-14489

  Poredos, Pavel ^a   Jezovnik, Mateja Kaja ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Atherosclerosis; Cardiovascular events; Preventive measures

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEBIVOLOL; PERINDOPRIL; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; RAMIPRIL; SIMVASTATIN; ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; WALKING; ANIMAL; CARDIOVASCULAR DISEASES; PERIPHERAL ARTERIAL DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; PERIPHERAL ARTERIAL DISEASE; SECONDARY PREVENTION;

EID: 84933556435     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160714477     Document Type: Review

References (53)

1. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685–1695
2. Clement, D.L.; Boccalon, H.; Dormandy, J.; Durand-Zaleski, I.; Fowkes, G.; Brown, T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int. Angiol. 2000, 19, 97–125
3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324, 71–86
4. Antithrombotic Trialists’ Collaboration; Baigent, C.; Blackwell, L.; Collins, R.; Emberson, J.; Godwin, J.; Peto, R.; Buring, J.; Hennekens, C.; Kearney, P.; et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373, 1849–1860
5. Berger, J.S.; Krantz, M.J.; Kittelson, J.M.; Hiatt, W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials. JAMA 2009, 301, 1909–1919
6. Fowkes, F.G.; Price, J.F.; Stewart, M.C.; Butcher, I.; Leng, G.C.; Pell, A.C.; Sandercock, P.A.; Fox, K.A.; Lowe, G.D.; Murray, G.D. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010, 303, 841–848
7. Poredos, P.; Jezovnik, M.K. Does the preventive effect of different drugs depend on location of the atherosclerotic process? Int. Angiol. 2008, 27, 274–280
8. Meadows, T.A.; Bhatt, D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 2007, 100, 1261–1275
9. Hovens, M.M.; Snoep, J.D.; Eikenboom, J.C.; van der Bom, J.G.; Mertens, B.J.; Huisman, M.V. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am. Heart J. 2007, 153, 175–181
10. Snoep, J.D.; Hovens, M.M.; Eikenboom, J.C.; van der Bom, J.G.; Huisman, M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch. Intern. Med. 2007, 167, 1593–1599
11. Kudoh, T.; Sakamoto, T.; Miyamoto, S.; Matsui, K.; Kojima, S.; Sugiyama, S.; Yoshimura, M.; Ozaki, Y.; Ogawa, H. Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease. Thromb. Res. 2006, 117, 263–269
12. Malinin, A.I.; Ong, S.; Makarov, L.M.; Petukhova, E.Y.; Serebruany, V.L. Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int. J. Clin. Pract. 2006, 60, 993–1002
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348, 1329–1339
14. McQuaid, K.R.; Laine, L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 2006, 119, 624–638
15. Coccheri, S. Antiplatelet drugs—Do we need new options? Drugs 2010, 70, 887–908
16. Bonaca, M.P.; Scirica, B.M.; Creager, M.A.; Olin, J.; Bounameaux, H.; Dellborg, M.; Lamp, J.M.; Murphy, S.A.; Braunwald, E.; Morrow, D.A. Vorapaxar in patients with peripheral artery disease results from TRA2°P-TIMI 50. Circulation 2013, 127, 1522–1529
17. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009, 361, 1045–1057
18. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360, 7–22
19. Coppola, G.; Novo, S. Statins and peripheral arterial disease: Effects on claudication, disease progression, and prevention of cardiovascular events. Arch. Med. Res. 2007, 38, 479–488
20. Paraskevas, K.I.; Hamilton, G.; Mikhailidis, D.P. Statins: An essential component in the management of carotid artery disease. J. Vasc. Surg. 2007, 46, 373–386
21. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267–1278
22. Aronow, W.S.; Ahn, C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug. Am. J. Cardiol. 2002, 90, 789–791
23. Pedersen, T.R.; Kjekshus, J.; Pyorala, K.; Olsson, A.G.; Cook, T.J.; Musliner, T.A.; Tobert, J.A.; Haghfelt, T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am. J. Cardiol. 1998, 81, 333–335
24. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251, 351–364
25. Aiello, F.A.; Khan, A.A.; Meltzer, A.J.; Gallagher, K.A.; McKinsey, J.F.; Schneider, D.B. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J. Vasc. Surg. 2012, 55, 371–379
26. Kumbhani, D.J.; Steg, P.G.; Cannon, C.P.; Eagle, K.A.; Smith, S.C.; Goto, S.; Ohman, E.M.; Elbez, Y.; Sritara, P.; Baumgartner, I.; et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: Insights from the REACH registry. Eur. Heart J. 2014, 35, 2864–2872
27. Westin, G.G.; Armstrong, E.J.; Bang, H.; Yeo, K.K.; Anderson, D.; Dawson, D.L.; Pevec, W.C.; Amsterdam, E.A.; Laird, J.R. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J. Am. Coll. Cardiol. 2014, 63, 682–690
28. Paraskevas, K.I.; Liapis, C.D.; Hamilton, G.; Mikhailidis, D.P. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur. J. Vasc. Endovasc. Surg. 2006, 32, 286–293
29. Schouten, O.; Boersma, E.; Hoeks, S.E.; Benner, R.; van Urk, H.; van Sambeek, M.R.; Verhagen, H.J.; Khan, N.A.; Dunkelgrun, M.; Bax, J.J.; et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N. Engl. J. Med. 2009, 361, 980–989
30. Mohler, E.R., III; Hiatt, W.R.; Creager, M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108, 1481–1486
31. Makin, A.; Lip, G.Y.; Silverman, S.; Beevers, D.G. Peripheral vascular disease and hypertension: A forgotten association? J. Hum. Hypertens. 2001, 15, 447–454
32. Hirsch, A.T.; Criqui, M.H.; Treat-Jacobson, D.; Regensteiner, J.G.; Creager, M.A.; Olin, J.W.; Krook, S.H.; Hunninghake, D.B.; Comerota, A.J.; Walsh, M.E. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286, 1317–1324
33. Kannel, W.B.; McGee, D.L. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J. Am. Geriatr. Soc. 1985, 33, 13–18
34. Ingolfsson, I.O.; Sigurdsson, G.; Sigvaldason, H.; Thorgeirsson, G.; Sigfusson, N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968–1986: A strong relationship to smoking and serum cholesterol—The Reykjavik Study. J. Clin. Epidemiol. 1994, 47, 1237–1243
35. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265, 3255–3264
36. Mehler, P.S.; Coll, J.R.; Estacio, R.; Esler, A.; Schrier, R.W.; Hiatt, W.R. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003, 107, 753–756
37. The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study: A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch. Intern. Med. 1991, 151, 1413–1423
38. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283, 1967–1975
39. Radack, K.; Deck, C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials. Arch. Intern. Med. 1991, 151, 1769–1776
40. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003, 21, 1011–1053
41. Kopecky, S.L. Effect of β blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am. J. Cardiol. 2006, 98, 1115–1119
42. Warner, G.T.; Perry, C.M. Ramipril: A review of its use in the prevention of cardiovascular outcomes. Drugs 2002, 62, 1381–1405
43. Ostergren, J.; Sleight, P.; Dagenais, G.; Danisa, K.; Bosch, J.; Qilong, Y.; Yusuf, S. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur. Heart J. 2004, 25, 17–24
44. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362, 782–788
45. Ahimastos, A.A.; Walker, P.J.; Askew, C.; Leicht, A.; Pappas, E.; Blombery, P.; Reid, C.M.; Golledge, J.; Kingwell, B.A. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. JAMA 2013, 309, 453–460
46. Shaw, J.E.; Zimmet, P.Z.; Alberti, K.G. Point: Impaired fasting glucose: The case for the new American Diabetes Association criterion. Diabetes Care 2006, 29, 1170–1172
47. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 2000, 342, 381–389
48. Camafort, M.; Alvarez-Rodriguez, L.R.; Munoz-Torrero, J.F.; Sahuquillo, J.C.; Lopez-Jimenez, L.; Coll, R.; Monreal, M.; Investigators, F. Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. Diabet. Med. 2011, 28, 73–80
49. CTDR Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 1995, 75, 894–903
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837–853
51. Selvin, E.; Wattanakit, K.; Steffes, M.W.; Coresh, J.; Sharrett, A.R. HbA1c and peripheral arterial disease in diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care 2006, 29, 877–882
52. Eurich, D.T.; Weir, D.L.; Majumdar, S.R.; Tsuyuki, R.T.; Johnson, J.A.; Tjosvold, L.; Vanderloo, S.E.; McAlister, F.A. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients. Circ. Heart Fail. 2013, 6, 395–402
53. Maca, T.; Mlekusch, W.; Doweik, L.; Budinsky, A.C.; Bischof, M.; Minar, E.; Schillinger, M. Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur. J. Clin. Investig. 2007, 37, 180–186.